These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 13783664)

  • 1. Studies on plasma kallikrein and its relationship to plasmin.
    WEBSTER ME; PIERCE JV
    J Pharmacol Exp Ther; 1960 Dec; 130():484-91. PubMed ID: 13783664
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin.
    Kleniewski J; Blankenship DT; Cardin AD; Donaldson V
    J Lab Clin Med; 1992 Jul; 120(1):129-39. PubMed ID: 1535355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of selective inhibitors against plasma kallikrein.
    Teno N; Wanaka K; Okada Y; Tsuda Y; Okamoto U; Hijikata-Okunomiya A; Naito T; Okamoto S
    Chem Pharm Bull (Tokyo); 1991 Nov; 39(11):2930-6. PubMed ID: 1839246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of tripeptide chloromethyl ketones and examination of their inhibitory effects on plasmin and plasma kallikrein.
    Tsuda Y; Teno N; Okada Y; Wanaka K; Bohgaki M; Hijikata-Okunomiya A; Okamoto U; Naito T; Okamoto S
    Chem Pharm Bull (Tokyo); 1989 Nov; 37(11):3108-11. PubMed ID: 2534361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent studies of the synthetic selective inhibitors; with special reference to non-plasmin fibrinolytic enzyme, plasmin and plasma-kallikrein.
    Okamoto S; Okamoto U; Hijikata-Okunomiya A; Wanaka K; Okada Y
    Thromb Res Suppl; 1988; 8():131-41. PubMed ID: 2974647
    [No Abstract]   [Full Text] [Related]  

  • 6. Structure-inhibitory activity relationship of plasmin and plasma kallikrein inhibitors.
    Tsuda Y; Tada M; Wanaka K; Okamoto U; Hijikata-Okunomiya A; Okamoto S; Okad Y
    Chem Pharm Bull (Tokyo); 2001 Nov; 49(11):1457-63. PubMed ID: 11724238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Characteristics of contact activation of rabbit blood (kallikrein and plasmin systems].
    Komissarova NV; Gomazkov OA
    Biull Eksp Biol Med; 1976; 81(4):390-2. PubMed ID: 132208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of human high molecular weight kininogen digestion by plasma kallikrein and by plasmin. A revised method of purification of high molecular weight kininogen.
    Kleniewski J; Donaldson VH
    J Lab Clin Med; 1987 Apr; 109(4):469-79. PubMed ID: 2950194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [General mechanisms of biochemical regulation of the kallikrein, clotting and fibrinolytic systems of the blood].
    Gomazkov OA; Komissarova NV
    Usp Sovrem Biol; 1976; 82(6):356-70. PubMed ID: 65846
    [No Abstract]   [Full Text] [Related]  

  • 10. Chromogenic peptide substrates. Their use for the assay of factors in the fibrinolytic and the plasma kallikrein-kinin systems.
    Friberger P
    Scand J Clin Lab Invest Suppl; 1982; 162():1-298. PubMed ID: 6221396
    [No Abstract]   [Full Text] [Related]  

  • 11. INTRAVASCULAR CLOTTING AND SPONTANEOUS FIBRINOLYSIS.
    KOLLER F
    Acta Haematol; 1964 Apr; 31():239-46. PubMed ID: 14169390
    [No Abstract]   [Full Text] [Related]  

  • 12. [Comparative evaluation of the kallikrein-kinin, plasmin and thrombin blood systems in hypertension].
    Karpitskiĭ VV
    Kardiologiia; 1983 Apr; 23(4):98-100. PubMed ID: 6223170
    [No Abstract]   [Full Text] [Related]  

  • 13. [Kinetics of in vitro fibrinolysis by plasmin and a plasmin-streptokinase equimolar complex].
    Aĭsina RB; Zhitkova IuV; Eremeev NL; Popova GIu; Kazanskaia NF
    Ukr Biokhim Zh (1978); 1991; 63(1):20-6. PubMed ID: 1827551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of oxytocin on fibrinolysis and the status of the kallikrein-kinin system].
    Kirichuk VF; Burova MB
    Probl Endokrinol (Mosk); 1989; 35(2):81-4. PubMed ID: 2740321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis.
    Joseph K; Tholanikunnel TE; Kaplan AP
    Ann Allergy Asthma Immunol; 2010 Jan; 104(1):50-4. PubMed ID: 20143645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation of kallikrein and plasmin inhibition capacity by aprotinin using a new assay to monitor therapy.
    Gallimore MJ; Fuhrer G; Heller W; Hoffmeister HE
    Adv Exp Med Biol; 1989; 247B():55-60. PubMed ID: 2481953
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of heparin on proteolytic activities in human plasma.
    Kongsgaard UE; Aasen AO; Smith-Erichsen N; Bjørnskau L
    Eur Surg Res; 1992; 24(2):119-28. PubMed ID: 1374715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interrelation of the blood kallikrein-kinin and anticoagulation systems in experimental myocardial infarct].
    Ponomareva AG; Churakov IuA; Trapezontseva RA; Stepanenko SB
    Kardiologiia; 1981 Jun; 21(6):89-93. PubMed ID: 6911343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of argatroban-induced endogenous thrombolysis by PKSI-527, and antibodies to TPA and UPA, evaluated in a rat arterial thrombolysis model.
    Hashimoto M; Oiwa K; Matsuo O; Ueshima S; Okada K; Okada Y; Okamoto S; Giddings JC; Yamamoto J
    Thromb Haemost; 2003 May; 89(5):820-5. PubMed ID: 12719778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [INDICATIONS AND HANDLING OF FIBRINOLYTIC ENZYME INHIBITORS].
    BERNARD J; BOUSSER J; DREYFUS B; HAMBURGER J; PEQUIGNOT H
    Presse Med (1893); 1964 Jan; 72():167-9. PubMed ID: 14106785
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.